Rapport Therapeutics reported robust Phase 2 data for RAP-219, a TARPγ8-specific AMPAR negative allosteric modulator for drug-resistant focal onset seizures. The open-label study demonstrated a 78% median reduction in clinical seizure frequency and a 71% decrease in electrographic seizure events, exceeding benchmarks for clinical benefit. Buoyed by these results, the company plans to initiate two Phase 3 trials. Investor enthusiasm propelled RAP’s shares over 190%, reflecting heightened expectations for this novel neurology candidate.